Study #2024-0321
A phase 1, open-label, multicenter study of INCB160058 in participants with myeloproliferative neoplasms.
MD Anderson Study Status
Enrolling
Treatment Agent
INCB160058
Description
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myeloproliferative Neoplasms
Study phase:
Phase I
Physician name:
Naveen Pemmaraju
Department:
Leukemia
For general questions about clinical trials:
1-855-493-3260
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.